Cancer immunotherapy‐targeted glypican‐3 or neoantigens

Immune checkpoint inhibitors have ushered in a new era in cancer therapy, although other therapies or combinations thereof are still needed for many patients for whom these drugs are ineffective. In this light, we have identified glypican‐3 an HLA‐24, HLA‐A2 restriction peptide with extreme cancer s...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Yasuhiro, Suzuki, Toshihiro, Yoshikawa, Toshiaki, Tsuchiya, Nobuhiro, Sawada, Yu, Endo, Itaru, Nakatsura, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Thematic Section: Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834776/
https://www.ncbi.nlm.nih.gov/pubmed/29285841
http://dx.doi.org/10.1111/cas.13485

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834776/
https://www.ncbi.nlm.nih.gov/pubmed/29285841
http://dx.doi.org/10.1111/cas.13485

Ejemplares similares